Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Aged ≥ 18 to ≤ 65 years~* A diagnosis of C1-INH HAE or FXII/PLG HAE;~* For subjects with C1-INH HAE: ≥ 4 HAE attacks over a consecutive 2-month period during the 3 months before Screening, as documented in the subject's medical record.~Exclusion Criteria:~* History of clinically significant arterial or venous thrombosis, or current clinically significant prothrombotic risk~* History of an uncontrolled, abnormal bleeding event due to a coagulopathy, or a current clinically significant coagulopathy or clinically significant risks for bleeding events~* Known incurable malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects with C1-INH HAE receiving buffer only
- CSL312 (low) (Type: ACTIVE_COMPARATOR): Subjects with C1-INH HAE receiving low dose CSL312
- CSL312 (med) (Type: ACTIVE_COMPARATOR): Subjects with C1-INH HAE receiving medium dose CSL312
- CSL312 (high) (Type: ACTIVE_COMPARATOR): Subjects with C1-INH HAE receiving high dose CSL312
- CSL312 (med/high) (Type: ACTIVE_COMPARATOR): Subjects with C1-INH HAE receiving medium/high dose CSL312

Based on this trial design, predict the completion outcome and termination type (if applicable).